Search Results

Alexandria Real Estate Equities, which focuses on development of life science and technology campuses, launched its inaugural member class of seed- and early-stage life science companies at the Alexandria LaunchLabs – Cambridge.

Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science, agtech and advanced technology mega campuses in AAA innovation cluster locations, today announced an exclusive partnership with longstanding tenant Eli Lilly and Company (NYSE: LLY) to expand Lilly’s innovative Gateway Labs model to the San Diego life science cluster.

The MeiraGTx founder and CEO, now on her third career, didn’t take a typical path.

Since the opening of Alexandria LaunchLabs at the Alexandria Center for Life Science – NYC in June 2017, its member companies have collectively raised more than $300 million in financing, with two of its companies completing IPOs

The new LaunchLabs incubator program is expected to open in 2020. This is the second incubator program Columbia University has become involved with this month.

The Alexandria Seed Capital Platform will be led by Alexandria Venture Investments and supported by a preeminent Advisory Board of seasoned biopharma and venture capital executives from Accelerator Life Science Partners, ARCH Venture Partners, Eli Lilly and Company, Pfizer and Roche.

Cambridge provides member companies with a unique, full-service platform featuring highly flexible, cost-effective, move‑in‑ready and well-equipped wet laboratory and office space; strategic programming and mentoring; and access to seed capital through the Alexandria Seed Capital Platform

Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, announced the execution of a long-term lease with Alexandria Real Estate Equities, Inc. for its new corporate headquarters.

Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration and growth of innovative healthcare and life science companies, announced the formation of a partnership program with Albert Einstein College of Medicine to support the development of novel therapeutics.

The site “represents a strategic opportunity to expand Alexandria’s unparalleled, world-class” life science development in the Boston area, said Peter Moglia, co-chief executive officer and co-chief investment officer of Alexandria.